Figure 1. Bridging the Gap Between Risk Detection and Preventive Action in Young Adults This figure highlights the role of AIP as a clinically accessible marker of adverse cardiometabolic risk, summarizes key barriers that currently limit its clinical actionability, and outlines potential future research priorities needed to support its implementation in younger populations. Arrows indicate the progression from risk identification to clinical challenges and then to potential directions for research and translation. AIP = atherogenic index of plasma; TG = triglycerides; HDL-C = high-density lipoprotein cholesterol; TRL = triglyceride-rich lipoproteins; sdLDL = small dense low-density lipoprotein; CVD = cardiovascular disease.
We only have this paper's title and publication details.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: